CELL INTELLIGENCE · 肿瘤细胞治疗研究

从静态风险到动态疾病监测：MRD 与免疫图谱在多发性骨髓瘤中的作用

From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

LLT1 过表达导致同种异体 NK 抵抗并促进增强型通用 CAR-T 细胞的生成

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.

根据这些结果，LLT1 过表达增强了 UCAR-T 细胞的活性并防止同种异体排斥反应，为通用型 CAR-T 细胞疗法的开发提供了重要见解。

CD38 特异性 CAR 整合到 CD38 基因座并由不同启动子驱动，导致 T 细胞和 NK 细胞具有不同的抗肿瘤活性

CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.

通过单细胞测序鉴定复发/难治性多发性骨髓瘤中 BCMA CAR-T 治疗后复发的潜在耐药机制和治疗靶点

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom

BCMA 靶向生物疗法：多发性骨髓瘤治疗的下一个标准治疗方案

BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.

多发性骨髓瘤 CAR-NK 细胞治疗的最新进展：细胞来源与靶抗原的综合综述

State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.

CAR-T 与 CAR NK 细胞的在靶脱瘤效应差异提示细胞治疗的疗效与安全性不同

Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies.

用 CD38 CAR 工程化 NK 细胞克服急性髓系白血病中 CD226 相关免疫逃逸

Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells.

多发性骨髓瘤免疫治疗：现状作为未来的序幕

Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.

靶向 CD38 和 LMP1 的 CAR-T 细胞对 NK/T 细胞淋巴瘤表现出强效抗肿瘤活性

CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma.

四种 CAR-T 细胞系在体外和体内均对 NKTCL 细胞表现出显著的细胞毒性。